 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Eliminationhalf-life | 2-2.5 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.043.012 |
| Chemical and physical data | |
| Formula | C17H22N4O |
| Molar mass | 298.390 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Minaprine (INN,USAN,BAN; brand namesBrantur,Cantor) is amonoamine oxidase inhibitorantidepressant drug that was used inFrance for the treatment ofdepression until it waswithdrawn from the market in 1996 because it causedconvulsions.[2][3]
A study found that it acts as areversible inhibitor of MAO-A (RIMA) in rats.[4] It has also been found to weaklyinhibitacetylcholinesterase in rat brain (striatum) homogenates.[5]
It has demonstrated significant antibiotic activity againstM. chelonae andM. abscessus in tests withantibiotic resistant bacteria.[6]
The first synthesis of minaprine was disclosed in patents published in 1979.[7]
The final step is the reaction between a chloro-substitutedpyridazine and theprimary amine group of amorpholine derivative.[7][8] The required pyridazine can be made by the reaction ofacetophenone andpyruvic acid, followed by ring formation usinghydrazine, giving a pyrazidinone. Treatment of this withphosphoryl chloride converts it to the required chloro derivative.[2]
